{"transactions":[{"id":882312,"issuer":{"id":8506,"kind":"organization","name":"Silexion Therapeutics Corp"},"owners":[{"id":64747,"kind":"person","name":"Noy Shlomo","position":1,"cik":"0002033211","reported_name":"Noy Shlomo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy ordinary shares)","published_at":"2026-02-25T16:23:33.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":10685,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Guangzhou Sino-Israel Biotech Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this row consists of the grant to GIBF by the Issuer of options to purchase ordinary shares, for director services provided by Avner Lushi (the Managing Partner and CEO of GIBF) to the Issuer, which grant was approved by the Issuer's board of directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as Chief Medical Officer of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein."}],"balance_after":10685,"derivative":{"exercise_price":1.65,"exercise_date":"2027-02-12","expiration_date":"2036-02-12","underlying":"Ordinary Shares","underlying_shares":10685},"source":{"system":"sec-edgar","filing":"0001178913-26-000644","document":"zk2634447.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2033211/000117891326000644/zk2634447.xml","form_type":"4"}},{"id":882311,"issuer":{"id":8506,"kind":"organization","name":"Silexion Therapeutics Corp"},"owners":[{"id":64747,"kind":"person","name":"Noy Shlomo","position":1,"cik":"0002033211","reported_name":"Noy Shlomo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-02-25T16:23:33.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":9091,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Guangzhou Sino-Israel Biotech Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this row consists of the grant to Guangzhou Sino-Israel Biotech Fund (\"GIBF\") by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share (\"ordinary shares\"), in respect of director services provided by Avner Lushi (the Managing Partner and CEO of GIBF) to the Issuer. The grant was approved by the Issuer's board of directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as Chief Medical Officer of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein."}],"balance_after":25399,"source":{"system":"sec-edgar","filing":"0001178913-26-000644","document":"zk2634447.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033211/000117891326000644/zk2634447.xml","form_type":"4"}},{"id":956646,"issuer":{"id":8506,"kind":"organization","name":"Silexion Therapeutics Corp"},"owners":[{"id":64747,"kind":"person","name":"Noy Shlomo","position":1,"cik":"0002033211","reported_name":"Noy Shlomo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy ordinary shares)","published_at":"2025-12-31T13:07:13.000Z","date":"2025-02-09","kind":"grant","planned":false,"acquired":true,"shares":1872,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Guangzhou Sino-Israel Biotech Fund"},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"Represents stock options granted by the Issuer to GIBF for director services provided by the Reporting Person and Avner Lushi (each, with respect to half of the options)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025."},{"field":"shares","element":"transactionShares","label":"F7","text":"The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"All of the stock options reported in this row vest (and become exercisable) on the first anniversary of the date of grant (i.e., on February 9, 2026), subject to the Reporting Person's or Mr. Lushi's (each, with respect to half of the options) continued service through such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F7","text":"The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this line by virtue of his serving as Chief Medical Officer of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein."}],"balance_after":1872,"derivative":{"exercise_price":18.9,"exercise_date":"2026-02-09","expiration_date":"2035-02-09","underlying":"Ordinary Shares","underlying_shares":1872},"source":{"system":"sec-edgar","filing":"0001178913-25-004147","document":"zk2534152.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2033211/000117891325004147/zk2534152.xml","form_type":"4"}},{"id":956645,"issuer":{"id":8506,"kind":"organization","name":"Silexion Therapeutics Corp"},"owners":[{"id":64747,"kind":"person","name":"Noy Shlomo","position":1,"cik":"0002033211","reported_name":"Noy Shlomo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-12-31T13:07:13.000Z","date":"2025-02-09","kind":"grant","planned":false,"acquired":true,"shares":1587,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Guangzhou Sino-Israel Biotech Fund"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents ordinary shares underlying RSUs granted to Guangzhou Sino-Israel Biotech Fund (\"GIBF\") by the Issuer for director services provided by the Reporting Person and Avner Lushi. The shares subject to this award vest in full on the first anniversary of the grant date, subject to the Reporting Person's or Mr. Lushi's (each, with respect to half of the shares) continued service through such date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents ordinary shares underlying RSUs granted to Guangzhou Sino-Israel Biotech Fund (\"GIBF\") by the Issuer for director services provided by the Reporting Person and Avner Lushi. The shares subject to this award vest in full on the first anniversary of the grant date, subject to the Reporting Person's or Mr. Lushi's (each, with respect to half of the shares) continued service through such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of ordinary shares reported in this row has been adjusted retroactively to reflect a 1-for-15 reverse share split effected by the Issuer on July 29, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of ordinary shares reported in this row has been adjusted retroactively to reflect a 1-for-15 reverse share split effected by the Issuer on July 29, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this line by virtue of his serving as Chief Medical Officer of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein."}],"balance_after":1587,"source":{"system":"sec-edgar","filing":"0001178913-25-004147","document":"zk2534152.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033211/000117891325004147/zk2534152.xml","form_type":"4"}}]}